Giant cell arteritis treatment patterns and rates of serious infectionsArticle Published on 2023-08-162024-09-04 Journal: Clinical and experimental rheumatology [Category] 대상포진, [키워드] GCA giant cell arteritis Glucocorticoids serious infection Treatment [DOI] 10.55563/clinexprheumatol/uonz1p PMC 바로가기 [Article Type] Article
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsBrief Report Published on 2023-02-202024-09-04 Journal: Advances in therapy [Category] 대상포진, [키워드] adverse events Baricitinib jak inhibitors MACE malignancy Mortality Safety serious infection VTE [DOI] 10.1007/s12325-023-02445-w PMC 바로가기 [Article Type] Brief Report
Nanopore-Targeted Sequencing Improves the Diagnosis and Treatment of Patients with Serious Infectionsarticle Published on 2023-01-182024-09-05 Journal: mBio [Category] update2024, [키워드] blood disease Diagnosis nanopore-targeted sequencing serious infection Treatment [DOI] 10.1128/mbio.03055-22 PMC 바로가기 [Article Type] article
Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections중환자 환경에서 COVID-19 과염증 환자의 토실리주맙 치료와 병원 획득 세균 및 침습성 진균 감염의 발병률 증가 사이의 연관성Article Published on 2022-08-012022-09-12 Journal: The Journal of hospital infection [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법, [키워드] 95% CI 95% confidence interval adverse event Bacterial Characteristics COVID-19 COVID-19 mortality COVID-19 secondary infections Critical care elevated Frequency Fungal infection fungal infections greater hospital discharge Hospital stay Hyperinflammatory ICU ICU admission incidence increase in inhibitor intensive care interleukin-6 invasive Invasive mechanical ventilation median Mortality Non-COVID-19 occurred outcome Patient patients with COVID-19 reduce reported retrospective review serious infection severe coronavirus disease severe COVID-19 significantly higher significantly lower Survivors Tocilizumab Treatment [DOI] 10.1016/j.jhin.2022.04.007 PMC 바로가기 [Article Type] Article
COVID-19 outbreak impact on health professionals: A survey on the Italian radiographer experienceResearch article Published on 2022-06-012022-10-05 Journal: Journal of medical imaging and radiation sciences [Category] COVID19(2023년), SARS, 진단, [키워드] Activation Computed tomography coronavirus COVID-19 COVID-19 outbreak COVID-19 positive patients diagnostic European country evaluate generate HCW Health high risk hospital Infection infection control involved Italian Italy majority management material men operator outbreak Patient patient safety performed Personal protective equipment Phase 1 PPE professional protocol Radiographers Radiography Radiological examinations Radiology Technologist Region responders Result Risk management SARS-CoV-2 serious infection Spread tomography worker X-ray X-ray computed [DOI] 10.1016/j.jmir.2022.02.006 [Article Type] Research article
Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTsCOVID-19 관리에서 표준 치료에 추가된 Tocilizumab: RCT의 메타 분석Meta-Analysis Published on 2022-03-142022-09-11 Journal: Acta bio-medica : Atenei Parmensis [Category] 임상, 진단, [키워드] 28-day mortality 95% CI addition Admission adverse event adverse events Analysis baseline benefit carried clinical benefit clinical benefits Cochrane Library control group Controlled controlled trials coronavirus disease Coronavirus disease 2019 COVID-19 defined Direct eligible event ICU ICU admission identify include initial intensive care intensive care unit less management mechanical ventilation Meta-analysis Mortality nine Occurrence Odds ratio outcome overall mortality participant Participants Patient performed Primary outcome progression randomization Randomized RCT RCTs receiving Science Science Direct secondary Secondary outcomes serious infection serious infections severe disease Standard of care statistically significant Steroids Subgroup analyses survival systematic review Tocilizumab use of steroid [DOI] 10.23750/abm.v93i1.12208 PMC 바로가기 [Article Type] Meta-Analysis
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trialCOVID-19 및 사이토카인 방출 증후군(COV-AID) 징후가 있는 환자에서 항인터루킨 약물의 효과: 요인, 무작위, 대조 시험Randomized Controlled Trial Published on 2021-12-012022-09-12 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단, [키워드] 95% CI assessment assigned baseline Belgium Block randomisation blockade C-reactive protein concentration center challenge Clinical improvement Complete Concentration Controlled trial COVID-19 Cytokine release syndrome D-dimer defined diagnosis of COVID-19 discharge drug Effect Efficacy Endpoint EudraCT evaluate Evidence factorial design failure ferritin fraction hazard ratio hospital hospitalised patient hypoxia hypoxic respiratory failure IL-1 IL-6 IL-6 blockade incidence intention-to-treat analysis intention-to-treat population interleukin International intravenously IQR lactate dehydrogenase less lymphopenia male mechanical ventilation median median age median time morbidity and mortality Mortality mortality risk Most patient multicentre Open-label oxygen PaO pathway Patient patients died patients with COVID-19 Primary outcome randomisation randomised Randomly receive Registered Safety safety population SARS-CoV-2 Serious Adverse Event serious infection serum single dose SOFA SOFA score Stratification study groups study outcome supplemental oxygen Symptom syndrome systemic cytokine therapeutic strategy Tocilizumab treatment group Trial were assessed with COVID-19 [DOI] 10.1016/S2213-2600(21)00377-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial입원한 성인 COVID-19(COV-BARRIER) 치료를 위한 바리시티닙의 효능 및 안전성: 무작위, 이중 맹검, 병행군, 위약 대조 3상 시험Clinical Trial Published on 2021-12-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 치료법, 치료제, [키워드] 1:1 95% CI Abstract addition all-cause mortality anti-inflammatory properties antivirals Asia assigned available data Baricitinib baseline Care Combination company Corticosteroids country death defined Dexamethasone Disease progression dose double-blind Efficacy and safety enrolled Europe evaluate event exploratory Follow-up French frequencies Frequency hazard ratio High-flow oxygen hospitalised inhibitor intention-to-treat population Invasive mechanical ventilation Janus kinase Japanese Lilly material Mortality non-invasive ventilation North America Odds ratio oxygen parallel-group participant Participants Phase 3 phase 3 trial Placebo placebo group placebo-controlled placebo-controlled trial prevented primary endpoint progressed proportion randomised Randomly receive receiving reduced reduction in Registered Remdesivir risk risk difference safety analyses safety analysis safety population safety profile secondary endpoint selective Serious Adverse Event Serious Adverse Events serious infection serious infections South America Spanish Standard Standard of care study drug systemic corticosteroid systemic corticosteroids the placebo group the primary endpoint thromboembolic translation Treatment two groups venous thromboembolic were assessed with COVID-19 [DOI] 10.1016/S2213-2600(21)00331-3 PMC 바로가기 [Article Type] Clinical Trial
The Disappearance of Respiratory Viruses in Children during the COVID-19 PandemicCOVID-19 팬데믹 기간 동안 어린이의 호흡기 바이러스 소실Article Published on 2021-09-102022-09-10 Journal: International Journal of Environmental Research an [Category] SARS, 치료기술, [키워드] absence analyzed childhood circulation COVID-19 declined detect disappearance Diseases Epidemic Face masks FIVE flu Health hospital Immunity Infection Influenza Influenza virus Intervention Italian lack Local macroscopic measure nasopharyngeal sample Nasopharyngeal samples pandemic pandemic spread Patient Public Public health interventions reduce reduction in related diseases respiratory respiratory infections respiratory symptom respiratory symptoms respiratory syncytial virus respiratory virus Respiratory virus infections respiratory viruses rhinovirus RSV serious infection serious infections social distancing social distancing measures spread of COVID-19 spreading susceptibility the epidemic Transmission Viral viral infections viral respiratory infection virus infections viruses were assessed [DOI] 10.3390/ijerph18189550 PMC 바로가기 [Article Type] Article
Coronavirus disease 2019 (COVID-19) era hospital infection controls reduce other serious infections and must be continued after the COVID-19 tragedy is resolvedLetter to the Editor Published on 2021-01-252022-10-30 Journal: Infection Control and Hospital Epidemiology [Category] Coronavirus, COVID19(2023년), MERS, SARS, [키워드] Coronavirus disease 2019 COVID-19 hospital infection control reduce resolved serious infection [DOI] 10.1017/ice.2021.11 PMC 바로가기 [Article Type] Letter to the Editor